Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Genentech

< Previous 1 2 3 4 5 Next >
Genentech’s Polivy Combination Reduced the Risk of Disease Worsening or Death by 27% in People With Previously Untreated Aggressive Form of Lymphoma
From Genentech
Via Business Wire
Tickers RHHBY
Interim Data From Phase III HAVEN 6 Study Demonstrate Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A
From Genentech
Via Business Wire
Tickers RHHBY
Genentech Presents Pivotal Data at ASH 2021 for Novel Cancer Immunotherapy Mosunetuzumab
From Genentech
Via Business Wire
Tickers RHHBY
New Data From the Phase II CITYSCAPE Trial Show Encouraging Results With Genentech’s Novel Anti-TIGIT Tiragolumab Plus Tecentriq
From Genentech
Via Business Wire
Tickers RHHBY
Genentech to Present New Pivotal Data at ASH 2021 From Broad and Comprehensive Portfolio, Challenging Treatment Standards for People With Blood Disorders
From Genentech
Via Business Wire
Tickers RHHBY
FDA Approves Genentech’s Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet Age-Related Macular Degeneration (AMD)
From Genentech
Via Business Wire
Tickers RHHBY
FDA Approves Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer
From Genentech
Via Business Wire
Tickers RHHBY
New 4-Year Data Show Genentech’s Enspryng (satralizumab-mwge) Significantly Reduces Debilitating Relapses in People With Neuromyelitis Optica Spectrum Disorder
From Genentech
Via Business Wire
Tickers RHHBY
New Data up to 8-Years for Genentech’s Ocrevus (ocrelizumab) Show Early and Ongoing Treatment Significantly Reduced Risk of Requiring a Walking Aid in Relapsing Multiple Sclerosis and Disability Progression in Primary Progressive Multiple Sclerosis
From Genentech
Via Business Wire
Tickers RHHBY
Genentech’s Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer’s Disease
From Genentech
Via Business Wire
Tickers RHHBY
Ad hoc announcement pursuant to Art. 53 LR: Genentech’s Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimer’s Disease
From Genentech
Via Business Wire
Tickers RHHBY
Genentech to Present New Data on Ocrevus (ocrelizumab) in Multiple Sclerosis and Enspryng (satralizumab-mwge) in Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2021
From Genentech
Via Business Wire
Tickers RHHBY
New Phase III Data Support the Benefit of Genentech’s Tecentriq in Early-stage Lung Cancer
From Genentech
Via Business Wire
Tickers RHHBY
Genentech to Present Data From Industry-Leading Portfolio at ESMO 2021 Showing Significant Progress in Early Stage and Uncommon Cancers
From Genentech
Via Business Wire
Tickers RHHBY
Genentech Provides Update on Tecentriq U.S. Indication for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
From Genentech
Via Business Wire
Tickers RHHBY
Phase III Study Shows Genentech's Polivy Plus R-CHP Is the First Regimen in 20 Years to Significantly Improve Outcomes in Previously Untreated Aggressive Form of Lymphoma Compared to Standard of Care
From Genentech
Via Business Wire
Tickers RHHBY
FDA Grants Priority Review to Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-small Cell Lung Cancer
From Genentech
Via Business Wire
Tickers RHHBY
FDA Accepts Application for Genentech’s Faricimab for the Treatment of Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)
From Genentech
Via Business Wire
Tickers RHHBY
Data for Genentech’s Evrysdi (risdiplam) Published in New England Journal of Medicine Shows Significant Improvement in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
Tickers RHHBY
FDA Grants Breakthrough Therapy Designation for Venclexta in Combination With Azacitidine for the Treatment of Patients With Myelodysplastic Syndromes
From Genentech
Via Business Wire
Tickers RHHBY
New Data for Genentech’s Hemlibra (emicizumab-kxwh) Reinforce Safety Profile in People With Hemophilia A
From Genentech
Via Business Wire
Tickers RHHBY
Genentech’s Actemra Receives FDA Emergency Use Authorization for the Treatment of COVID-19 In Hospitalized Adults and Children
From Genentech
Via Business Wire
Tickers RHHBY
FDA Accepts Application for Genentech’s Port Delivery System With Ranibizumab (PDS) for Treatment of Wet Age-Related Macular Degeneration (AMD)
From Genentech
Via Business Wire
Tickers RHHBY
Genentech Announces Data at EHA2021 Reinforcing Efficacy of Venclexta Combinations in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
From Genentech
Via Business Wire
Tickers RHHBY
New Genentech Data for Evrysdi (risdiplam) Show Improved Motor Function in Pre-Symptomatic Babies After One Year and Confirm Safety Profile in Previously Treated People With Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
Tickers RHHBY
Genentech Presents Latest Advances With Immunotherapies in Non-Hodgkin’s Lymphoma
From Genentech
Via Business Wire
Tickers RHHBY
Pivotal Phase III Data at ASCO Show Genentech’s Tecentriq Helps Certain People With Early Lung Cancer Live Significantly Longer Without Their Disease Returning
From Genentech
Via Business Wire
Tickers RHHBY
Genentech to Present Data From One of the Most Comprehensive Oncology Portfolios at the 2021 ASCO Annual Meeting Showcasing Advancements for People Living With Cancer
From Genentech
Via Business Wire
Tickers RHHBY
FDA Advisory Committee Votes in Favor of Maintaining Accelerated Approval of Genentech’s Tecentriq for Previously Untreated Metastatic Bladder Cancer
From Genentech
Via Business Wire
Tickers RHHBY
FDA Advisory Committee Votes in Favor of Maintaining Accelerated Approval of Genentech’s Tecentriq for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer
From Genentech
Via Business Wire
Tickers RHHBY
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.